Clinical trialNCT00434850CompletedPhase 2Interventional

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment14Diabetes Mellitus, Type 1

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess the safety and efficacy of deoxyspergualin (DSG), an immunosuppressant drug, on post-transplant islet function in people with type 1 diabetes who have not responded to intensive insulin therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Andrew Posselt, MD, PhD
University of California, San Francisco
Principal Investigator
clinicaltrials.gov ↗
Bernhard Hering, MD
University of Minnesota
Principal Investigator
clinicaltrials.gov ↗
Xunrong Luo, MD, PhD
Northwestern University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Californinia, San Francisco
San Francisco, California, United States
Northwestern University
Chicago, Illinois, United States
University of Minnesota
Minneapolis, Minnesota, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Allogeneic Pancreatic Islet CellsAntithymocyte globulinDaclizumab or basiliximabDeoxyspergualinEtanercept →Sirolimus →Tacrolimus →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2006
Primary completion: 30 Sept 2011
Completion: 30 Nov 2013
Last update posted: 16 Mar 2016
Registered enrollment: 14
Registry id: NCT00434850

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.